- Policy
- The MFDS reviews Pfizer's vaccine permission for infants
- by Lee, Hye-Kyung Sep 2, 2022 06:03am
- The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) announced on the 1st that Pfizer Korea has begun reviewing the item as it applied for permission for imported items of the early COVID-19 vaccine for infants (6 months to 4 years old). The efficacy of "Comirnati 0.1mg/mL (for ages 6 months to 4 years)" applied this time is "Preve
- Policy
- Tylenol ER, voluntarily withdrawn, will be maintained
- by Kim, Jung-Ju Sep 2, 2022 06:03am
- Along with the withdrawal of Janssen Korea's Hyangnam plant, the suspension for Tylenol ER 8 hrs and children's Tylenol suspension, which were voluntarily withdrawn due to item maintenance, will be maintained until this year. The insurance drug product code of nursing institutions will continue to be maintained until the end of the year and c
- Policy
- Advance reservations for SKYCovione will begin on the 1st
- by Kim, Jung-Ju Sep 2, 2022 06:02am
- The inoculation of the COVID-19 vaccine SKYCovione developed by SK Bioscience has begun in earnest. Starting with pre-booking tomorrow (1st), day-to-day and door-to-door vaccinations will be started from the 5th. In addition, the COVID-19 bivalent vaccine will be introduced and vaccinated in the fourth quarter of this year. Lee Ki-il, the
- Policy
- MFDS sets next year's budget at ₩669.4 billion
- by Lee, Hye-Kyung Sep 1, 2022 05:56am
- The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) had compiled its budget plan for 2023 at &8361;669.4 billion, a &8361;5.4 billion (0.8%) increase from the &8361;664 billion that had been set for this year. The next year’s budget proposal is focused on the definite implementation of the new administration’s national tasks &
- Policy
- Coverage of 19 new drug items will be reinforced this year
- by Kim, Jung-Ju Aug 31, 2022 05:40am
- [Nineteen new drugs have been newly listed on the pharmaceutical reimbursement list or expanded reimbursement standards from January to this month this year. Among the drugs, 4 items were newly listed drugs, and 2 were already-listed drugs receiving reimbursement expansions. An estimated 1,320,371 patients will benefit from the new drug cove
- Policy
- Reevaluation of Amosartan plus & Twotops Plus
- by Lee, Tak-Sun Aug 30, 2022 05:55am
- Hanmi's Amosartan plus & Twotops plus cause the same formulation, whether or not listed. The Ministry of Health and Welfare announced the plan to revalue the addition in November 2020, and said that IMD will maintain its addition if the number of companies with the same product registered, individual single agents, complex agents, and admin
- Policy
- Lorviqua reimb at ₩52,819, Emgality at ₩295,250
- by Kim, Jung-Ju Aug 30, 2022 05:55am
- ◆Lorviqua Tab= Lorviqua is a treatment that received domestic marketing authorization as monotherapy to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). The company applied for reimbursement after receiving approval from the Ministry of Food and Drug Safety on July 29
- Policy
- Zemimet’s price drops 9.7% in 5 years…discounted 5 times
- by Lee, Tak-Sun Aug 30, 2022 05:54am
- LG Chem’s incrementally modified new diabetes treatment, ‘Zemimet Tab,’ has once again been subject to Price-Volume Agreement negotiations this year and its price will be discounted as of the 1st of next month. This is the fifth price cut made through the PVA system for the drug since its reimbursement approval. Its price had fallen nearly
- Policy
- Kyowa Hakogirtin Postelligeo 20mg is expected to be approved
- by Lee, Hye-Kyung Aug 30, 2022 05:54am
- Posteligeo 20mg, a rare two-type non-Hodgkin lymphoma treatment of Kyowa Hakogirin, is expected to be approved. It has been four years since the U.S. Food and Drug Administration (FDA) approved the treatment of mycosis fungoids (MF) or S&233;zary syndrome (SS) in August 2018. According to the pharmaceutical industry on the 26th, the Ministry
- Policy
- "Raise the prescription rate for high-risk patients to 50%"
- by Lee, Jeong-Hwan Aug 29, 2022 06:03am
- Experts have pointed out that high-risk patients with COVID-19 should be first administered oral treatments such as Paxlovid or Lagevrio etc. before hospitalization. In other words, if the prescription rate of oral COVID-19 treatments remains in the current 20% range, experts believe that the prescriptions will not be sufficient to prev
